arterial disease News
-
InspireMD Commences Trading on Nasdaq-CM
InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital Market (“Nasdaq-CM”), today, May 21, 2021, under the symbol NSPR. InspireMD CEO Marvin Slosman said, “The trading of our ...
-
CathWorks FFRangio System Receives Regulatory Approval in Japan
CathWorks today announced the approval of The CathWorks FFRangio™ System by the Japan’s Ministry of Health, Labour and Welfare (MHLW). The CathWorks FFRangio System is a non-invasive diagnostic technology that is used at the time of a routine angiography. The CathWorks FFRangio System transforms routine angiogram images into objective and comprehensive physiology information, ...
By CathWorks
-
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021. Mr. Slosman will deliver his corporate ...
-
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021. Chief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021. ...
-
BioMimics 3D Vascular Stent System granted Shonin in Japan – December 2019
The BioMimics 3D Vascular Stent System received Shonin regulatory approval in Japan. On December 19th, 2019, Japanese MHLW PMDA granted Marketing Pre-Market Approval (“Shonin”) for BioMimics 3D Vascular Stent System to improve luminal diameter during endovascular intervention in patients with symptomatic peripheral arterial disease in the femoropopliteal artery. The approved ...
-
CathWorks FFRangio System Receives National Reimbursement Approval in Japan
CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System, making it more broadly available for coronary artery disease decision-making in Japan. The CathWorks FFRangio™ System has already received regulatory approval from the Japanese Pharmaceuticals and Medical Devices ...
By CathWorks
-
InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update -Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens. Management will host a conference call aand webcast with the investment community at 8:30 am ...
-
CathWorks FFRangio System Case Review - Highlight from Dr. Rahul Sharma’s CVIT Presentation
The CathWorks FFRangio System is revolutionizing treatment decisions for coronary artery disease with quick, non-invasive, wire-free 3D FFR guidance. In this excerpt from his webinar presentation at CVIT Japan 2021, Dr. Rahul P. Sharma, MBBS, FRACP, Director of Structural Interventions at Stanford Medical Center, presents a case study that demonstrates the highly accurate multi-vessel FFR ...
By CathWorks
-
Mike Feher Appointed as CFO of CathWorks
CathWorks, a global leader of digital health innovation focused on helping patients with cardiovascular disease, announced today that Mike Feher was appointed Chief Financial Officer, effective immediately. An energetic and results-driven executive, Mr. Feher brings comprehensive strategic and operational finance experience to his role, including expertise in financial planning and analysis, ...
By CathWorks
-
Soundbite Medical Enters Into A License Agreement With VFLO Medical To Bring Its Products To Greater China
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that it has entered into an exclusive license agreement with VFLO Medical (VFLO). Pursuant to the agreement, Soundbite has granted to VFLO an exclusive license for certain proprietary ...
-
Reva Medical Presents 6-Month Results from Motiv BTK Pilot Study
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. Prof. Thomas Rand, MD from the Klinik Floridsdorf Vienna, Austria presented the initial ...
-
Soundbite Medical Announces Issuance Of A Fifth U.S. Patent Covering Novel Active Balloon Devices Intended For Plaque Modification Of Calcified Arteries
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific occlusive peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office has issued US patent No. 11,179,169, entitled “Device for delivering mechanical waves through a balloon catheter”. The ...
-
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National ...
-
SoundBite Medical Solutions Announces First Use of its Novel 0.014” Active Wire to Successfully Treat Calcified Below-The-Knee CTOs
Soundbite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014” platform in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified below-the-knee (BTK) chronic total occlusions (CTO). The procedures were performed by Professor Marianne Brodmann, Head of the Clinical Division of Angiology, Department of ...
-
CARDIONOVUM announces the first Signature RCT patient enrollment
CARDIONOVUM announced today the first Signature Randomized Clinical Trial patient enrolment. On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled. Dr. Ralf Langhoff, P.I. of the study, stated “I believe that this randomized study will confirm, once more, the efficacy and the safety of the Legflow® DCB in the daily treatment of ...
-
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina
XyloCor Therapeutics today announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina. The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary ...
-
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its ...
-
Infraredx, a Nipro Company, Announces Enrollment of First Patient in EXPANSE PTCA study.
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the Lacrosse NSE ...
-
Reva Medical Announces Final 5 Year Results for It’s Fantom II Coronary Scaffold Study
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications is pleased to announce exceptional 5 Year clinical results from its FANTOM II Study. The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United ...
-
Reva medical announces closing of strategic financing
REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing. This funding was led by a global strategic investor with deep experience in medical devices, as well as BioStar Capital, and existing investors. Proceeds from the financing ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you